Earlier this month, the Food and Drug Administration (FDA) approved Lexapro (escitalopram oxalate) for the acute and maintenance treatment of major depressive disorder (MDD) in adolescents 12- to 17-years-old.
Here's some basic information about the approval from a Forest Laboratories press release (I have put some parts in bold for added attention):
"The approval of Lexapro for the treatment of adolescent depression was supported by two placebo-controlled studies, one conducted in...
